Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Reddit CEO & President Steve Ladd Huffman Sells $2.74M of Stock
Steve Ladd Huffman, CEO & President, sold 17,308 shares of Reddit, Inc. at $155.33 to $163.72 a share (average $158.57) in 9 transactions, worth $2.74M in total on Oct 13, 2026. Shares held after the trade: 336,432 (-0.1%).
Bluerock Private Real Estate Fund President Jordan B. Ruddy Buys $44.3K of Stock
Jordan B. Ruddy, President, bought 3,520 shares of Bluerock Private Real Estate Fund at $12.59 a share, worth $44.3K in total on Oct 14, 2026. Shares held after the trade: 17,192 (+25.7%).
Varonis is positioned as a critical enabler for GenAI deployment, specifically solving data overexposure and permission management risks that otherwise stall AI adoption.
Terrestrial Energy Director Charles G. Pardee Buys $22.1K of Stock
Charles G. Pardee, Director, bought 7,500 shares of Terrestrial Energy Inc. at $2.95 a share, worth $22.1K in total on Oct 14, 2026. Shares held after the trade: 14,258 (+111.0%).
Interactive Brokers delivered record pre-tax income and 78% margins, driven by 30% account growth and higher interest income despite a 15% decline in Fed funds rates.
Crispr Therapeutics General Counsel and Secretary James R. Kasinger Sells $51.2K of Stock
James R. Kasinger, General Counsel and Secretary, sold 1,040 shares of Crispr Therapeutics AG at $49.26 a share, worth $51.2K in total on Oct 14, 2026. Shares held after the trade: 95,857 (-1.1%).
Crispr Therapeutics CEO Samarth Kulkarni Sells $202K of Stock
Samarth Kulkarni, CEO, sold 4,098 shares of Crispr Therapeutics AG at $49.26 a share, worth $202K in total on Oct 14, 2026. Shares held after the trade: 259,736 (-1.6%).
Park Aerospace reported Q2 sales of $20.79M, meeting guidance, while navigating aggressive missile system ramps and GE engine program delays through significant capacity expansions in Tulsa and France.
Northrim BanCorp reported Q3 2026 net income of $14.4 million, or $0.63 per diluted share, impacted by an $8.8 million impairment charge related to a single specialty finance customer relationship. Despite the charge, the company achieved record net interest income and a net interest margin of 5.02% while continuing to progress on its pending acquisition of PBCO Financial Corporation.
Term
Q3 2026
“Record net interest income, strong deposit growth and a net interest margin above 5% drove a 21% increase in pre-provision net revenue in the third quarter. Our earnings this quarter were reduced by a higher provision for credit losses tied to a single relationship in our Specialty Finance segment.”
Mike Huston, Northrim's President and Chief Executive Officer
“We continue to make progress toward completing our acquisition of PBCO Financial Corporation, which we announced in July. The combination is intended to extend our relationship-driven banking model into attractive markets in Southern Oregon and the Willamette Valley and create a company with more than $4 billion in assets.”
Mike Huston, Northrim's President and Chief Executive Officer
River Financial Corporation reported its third quarter 2026 financial results, highlighted by a 41% increase in quarterly net income to $15.1 million. The company saw significant growth in its balance sheet, with total assets surpassing $4 billion and tangible book value per share increasing 12.6% year-over-year to $37.03.
Ares Industrial Real Estate Income Trust Business Update
Ares Industrial Real Estate Income Trust reported its monthly Net Asset Value (NAV) update, with an Aggregate Fund NAV of approximately $5.10 billion as of September 30, 2026. The company's total investment portfolio, primarily consisting of industrial properties, was valued at $10.41 billion. The filing also confirmed the engagement of Altus Group U.S. Inc. as the independent valuation advisor for the portfolio.
Ernexa Therapeutics Inc. has made available a formal investor presentation for October 2026. The presentation is intended to provide strategic updates and company information to investors and is accessible via the company's investor relations website.
Transocean $750M Debt Financing with Citibank, N.A.
Transocean entered into an amended and restated credit agreement to increase its revolving credit facility from $510 million to $750 million and extend the maturity to October 2031. The effectiveness of the facility is contingent upon the closing of Transocean's previously announced acquisition of Valaris Limited. Additionally, the company retired $165 million of its 8.00% Senior Secured Notes due 2028 using cash on hand.
Ares Real Estate Income Trust Inc. provided its monthly update for September 30, 2026, reporting an Aggregate Fund Net Asset Value (NAV) of approximately $3.97 billion. The company's total real estate portfolio value increased to $9.27 billion from $9.03 billion in the prior month, driven primarily by growth in residential and industrial property investments.
FG Communities Holdings M&A Deal with unaffiliated third party
FG Communities Holdings Inc. completed the acquisition of two manufactured housing communities in North Carolina, located in Garner and Mars Hill. The acquisitions added a combined 78 homesites across 78 acres to the company's portfolio and were funded using cash on hand.
Rithm Perpetual Life Residential Trust Business Update
Rithm Perpetual Life Residential Trust released its Net Asset Value (NAV) per share for the period ending September 30, 2026. The company reported a total NAV of $164.7 million, with Class J shares valued at $20.1472 and Class E shares at $20.3299.
Qualys CEO & President Sumedh S. Thakar Sells $609K of Stock
Sumedh S. Thakar, CEO & President, sold 3,200 shares of Qualys, Inc. at $188.03 to $194.30 a share (average $190.36) in 5 transactions, worth $609K in total on Oct 14, 2026. Shares held after the trade: 177,138 (-0.2%).
Opus Genetics presented positive clinical data from its OPGx-BEST1 and OPGx-LCA5 gene therapy programs at the Retina in Rio 2026 conference. OPGx-BEST1 showed improved retinal sensitivity in 75% of Cohort 1 participants, while OPGx-LCA5 demonstrated sustained visual improvements through 24 months in adults and 6 months in pediatric patients.
Mount Logan Capital $15M Debt Financing with MLC US Holdings LLC
Mount Logan Capital's subsidiary, MLC US Holdings LLC, entered into Amendment No. 6 to its Credit Agreement to obtain a limited waiver for defaults related to the merger of Alternative Credit Income Fund into BC Partners Lending Corporation. As part of the transaction, a $15 million promissory note previously pledged as collateral was cancelled and replaced by rights to a revenue share agreement.
Semtech Corporation held a Data Center Analyst Day where it raised its third quarter fiscal year 2027 outlook and established a long-term financial framework for fiscal year 2030. The company now expects Q3'27 net sales of $417.5 million and adjusted EPS of $1.14, while targeting $3.2 billion in total net sales by FY2030 driven by significant growth in its data center business.
Varonis Systems Signs $6.3B M&A Deal with Proofpoint, Inc.
Varonis Systems has entered into a definitive agreement to be acquired by Proofpoint, Inc., a portfolio company of Thoma Bravo, in an all-cash transaction valued at approximately $6.3 billion. Varonis shareholders will receive $49.75 per share in cash, representing a 52% premium to the company's unaffected stock price. The deal is expected to close in the first half of 2027 and will create a unified cybersecurity platform focused on data and AI security.
Biohaven Licensing Deal with Ono Pharmaceutical Co., Ltd. Worth $100M
Biohaven granted Ono Pharmaceutical an exclusive license to develop and commercialize its MoDE pan IgG degrader portfolio, including lead candidate BHV-1300, in Japan, South Korea, Taiwan, and ASEAN countries. Biohaven receives an $80 million upfront payment and is eligible for a $20 million milestone payment plus royalties of approximately 20% on net sales in the territory.
Cenntro Inc. entered into a sales agreement with Pacific Century Securities, LLC to establish an at-the-market (ATM) offering program. Under the agreement, the company may sell up to $100 million of its common stock from time to time, though it is not obligated to sell any shares and no sales were reported in this filing.
SPACSphere Acquisition M&A Deal with Mobilewalla Holdco, Inc.
SPACSphere Acquisition Corp. entered into an amendment to its existing business combination agreement with Mobilewalla Holdco, Inc. to increase the size of the post-merger board of directors from five to seven members. The amendment also specifies the initial director designees for the combined company, which will be renamed Covariate, Inc. upon the closing of the transaction.
Vivakor Debt Financing Update with J.J. Astor & Co.
Vivakor, Inc. issued 878,255 shares of common stock to J.J. Astor & Co. following the conversion of $1,972,472.08 in principal and interest under a junior secured convertible promissory note. This conversion satisfies the company's remaining obligations under the $5.94 million note originally issued in July 2025.
PreAxia Health Care Payment Systems Inc. reported a net loss of $206,876 for the three months ended August 31, 2026, on zero revenue as its products remain in the development stage. The company's cash position improved significantly to $141,579 due to $228,000 in proceeds from convertible debt notes, though it continues to operate with a shareholders' deficit of $543,336.
Lemonade, Inc. disclosed compensation terms for its leadership transition effective January 1, 2027, including an employment agreement for incoming CFO Nick Stead with a $412,500 base salary and 80,000 RSUs. Outgoing CFO Tim Bixby will transition to the Board of Directors, receiving a $50,000 annual cash retainer and $185,000 in annual RSU awards under the non-employee director policy.
ChronoScale Holdings reported fiscal Q1 2027 revenue of $41.5 million, a 148% year-over-year increase, following its strategic shift toward AI infrastructure. The company completed the divestiture of its legacy Ekso business and secured a major 50 MW AI compute deployment with Microsoft.
Term
Q1 2027
“We believe our strong revenue growth and expanded customer commitments validate the demand we are seeing and our opportunity to grow alongside our customers. Our Microsoft deployment and partnerships with Nutanix and Baseten should position us to serve hyperscale and enterprise AI demand, while the completed Ekso sale is intended to allow us to sharpen our focus on AI infrastructure. With our customer agreements and current deployment schedule supporting an expected $1 billion in annualized revenue run rate by calendar Q3 2027, our priority is disciplined execution and delivering the infrastructure our customers need at scale.”
Cenly Chen, Chief Executive Officer of ChronoScale
BeOne Medicines Insider Xiaodong Wang Sells $10.9M of Stock
Xiaodong Wang sold 31,027 shares of BeOne Medicines Ltd. at $349.56 to $353.24 a share (average $350.99) in 5 transactions, worth $10.9M in total on Oct 13, 2026. Shares held after the trade: 0 (-100.0%).
Actinium Pharmaceuticals appointed Matt David, M.D., as Chief Financial Officer, effective October 14, 2026. Dr. David's compensation package includes a $450,000 base salary, a $150,000 sign-on bonus, and an inducement grant of 250,000 stock options and 325,000 restricted stock units.